Practice-Based Evidence: Profiling the Safety of Cilostazol by Text-Mining of Clinical Notes
Open Access
- 23 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5), e63499
- https://doi.org/10.1371/journal.pone.0063499
Abstract
Peripheral arterial disease (PAD) is a growing problem with few available therapies. Cilostazol is the only FDA-approved medication with a class I indication for intermittent claudication, but carries a black box warning due to concerns for increased cardiovascular mortality. To assess the validity of this black box warning, we employed a novel text-analytics pipeline to quantify the adverse events associated with Cilostazol use in a clinical setting, including patients with congestive heart failure (CHF). We analyzed the electronic medical records of 1.8 million subjects from the Stanford clinical data warehouse spanning 18 years using a novel text-mining/statistical analytics pipeline. We identified 232 PAD patients taking Cilostazol and created a control group of 1,160 PAD patients not taking this drug using 1∶5 propensity-score matching. Over a mean follow up of 4.2 years, we observed no association between Cilostazol use and any major adverse cardiovascular event including stroke (OR = 1.13, CI [0.82, 1.55]), myocardial infarction (OR = 1.00, CI [0.71, 1.39]), or death (OR = 0.86, CI [0.63, 1.18]). Cilostazol was not associated with an increase in any arrhythmic complication. We also identified a subset of CHF patients who were prescribed Cilostazol despite its black box warning, and found that it did not increase mortality in this high-risk group of patients. This proof of principle study shows the potential of text-analytics to mine clinical data warehouses to uncover ‘natural experiments’ such as the use of Cilostazol in CHF patients. We envision this method will have broad applications for examining difficult to test clinical hypotheses and to aid in post-marketing drug safety surveillance. Moreover, our observations argue for a prospective study to examine the validity of a drug safety warning that may be unnecessarily limiting the use of an efficacious therapy.Keywords
This publication has 38 references indexed in Scilit:
- Unified Medical Language System term occurrences in clinical notes: a large-scale corpus analysisJournal of the American Medical Informatics Association, 2012
- Low lifetime recreational activity is a risk factor for peripheral arterial diseaseJournal of Vascular Surgery, 2011
- A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudicationVascular Medicine, 2010
- Comparison of concept recognizers for building the Open Biomedical AnnotatorBMC Bioinformatics, 2009
- Recognizing Obesity and Comorbidities in Sparse DataJournal of the American Medical Informatics Association, 2009
- One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United StatesCirculation: Cardiovascular Quality and Outcomes, 2008
- Genome-wide association studies for common diseases and complex traitsNature Reviews Genetics, 2005
- Exploring semantic groups through visual approachesJournal of Biomedical Informatics, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study)The American Journal of Cardiology, 2001